Cargando…
The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis
The prognostic value of cancer stem cells (CSCs) marker CD133 in non-small-cell lung cancer (NSCLC) remains controversial. We performed this meta-analysis of 32 eligible studies to clarify the prognostic value of CD133 and provide evidence for CSCs hypothesis. We calculated pooled hazard ratio (HR)...
Autores principales: | Chen, Engeng, Zeng, Zhiru, Bai, Bingjun, Zhu, Jing, Song, Zhangfa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302932/ https://www.ncbi.nlm.nih.gov/pubmed/27489355 http://dx.doi.org/10.18632/oncotarget.10964 |
Ejemplares similares
-
The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients
por: Izycka, Natalia, et al.
Publicado: (2023) -
CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation
por: Zhang, Lin, et al.
Publicado: (2016) -
Human cytomegalovirus infection and colorectal cancer risk: a meta-analysis
por: Bai, Bingjun, et al.
Publicado: (2016) -
TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133(+) A549 cell fraction
por: Tirino, V, et al.
Publicado: (2013) -
Cancer stem cells (CSCs), cervical CSCs and targeted therapies
por: Huang, Ruixia, et al.
Publicado: (2016)